A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer
Terminated · Phase 2 · NCT05169684
Conditions: Prostatic Neoplasms, Castration-Resistant
At a glance
- Research payments reported, 2025
- $7,165
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 10
About the trial
- Sponsor
- Bristol-Myers Squibb
- Tested
- BMS-986218 (biological), Docetaxel (drug), Nivolumab (biological)
- Dates
- Started 2022-02-14; completion 2023-12-06
- Results posted
- Yes
The purpose of this study is to assess the safety, efficacy, tolerability, and toxicity of docetaxel alone, in combination with BMS-986218, or in combination with nivolumab plus BMS-986218 in men who have metastatic castration-resistant prostate cancer (mCRPC) that progressed after novel antiandrogen therapy and have not received chemotherapy for mCRPC.
From ClinicalTrials.gov, last updated 2025-06-10. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $7,165 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Virginia Oncology Associates $7,165
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.